Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.
Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.
iSpecimen (Nasdaq: ISPC) reported the completion of a large-scale international cancer research order involving hundreds of cancer blood specimens, shipped within three weeks of receiving the purchase order. The company used its global network of healthcare institutions, labs, biobanks, and research partners to source, collect, and internationally fulfill specialized cancer biospecimens, including FFPE and flash-frozen tissue, highlighting its focus on rapid, efficient biospecimen sourcing for time-sensitive research projects.
iSpecimen (Nasdaq: ISPC) announced the closing of its previously announced public offering totaling approximately $5.0 million in aggregate purchase price. The transaction includes 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 additional common shares.
According to iSpecimen, net proceeds are intended for repayment of outstanding liabilities, potential acquisitions or investments in businesses, products and technologies, marketing and advertising services, and general working capital. E.F. Hutton & Co. acted as exclusive placement agent. The securities were offered under an effective Form S-1 registration statement (File No. 333-297001) declared effective on July 30, 2026.
iSpecimen (Nasdaq: ISPC) priced a public offering of approximately $5 million of common stock and/or pre-funded warrants at a public offering price of $1.30 per share, or $1.2999 per pre-funded warrant, reflecting the $0.0001 per share exercise price of each pre-funded warrant.
According to iSpecimen, net proceeds are expected to be used to repay outstanding liabilities, fund potential asset or business acquisitions, support investments in products and technologies, and pay for marketing and advertising services, with the remainder allocated to working capital. E.F. Hutton & Co. is acting as exclusive placement agent. The offering is expected to close on August 7, 2026, subject to customary conditions, under an effective SEC Form S‑1 registration statement.
iSpecimen (Nasdaq: ISPC) priced a private placement for aggregate gross proceeds of approximately $2.5 million, issuing 488,281 common shares at $5.12 per share and offering pre-funded warrants at $5.1199 where exercisable for one share at $0.0001 per share.
The company intends to use net proceeds for working capital, including up to $900,000 for marketing. The offering is expected to close on or about May 11, 2026, is capped at 19.99% of outstanding shares pending stockholder approval, and E.F. Hutton serves as placement agent.
iSpecimen (NASDAQ: ISPC) will effect a 1-for-40 reverse stock split effective 4:30 p.m. ET on April 27, 2026, with split-adjusted trading beginning on April 28, 2026. The company will retain the ticker ISPC and receive new CUSIP 45032V306.
Outstanding shares will be reduced from 52,639,796 to 1,316,032. Options, warrants, RSUs and plan reserves will be proportionally adjusted; fractional shares will be rounded up to whole shares at the participant level. The company said the split is intended to raise the per-share trading price and help satisfy Nasdaq minimum bid requirements.
iSpecimen (NASDAQ: ISPC) implemented a direct shipping model that cuts human biospecimen transit times by ~70–85% and enables domestic deliveries in as little as 1–2 days.
The change reduces reliance on central hubs, lowers shipping handoffs and costs, and pairs with strengthened European and Eastern European supplier partnerships to improve access to rare specimens and consistency for international requests.
iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone for influenza research on March 16, 2026, collecting approximately 500 influenza swab samples over several weeks to support a customer project.
The company also maintained supply of cerebrospinal fluid (CSF), and noted rising demand for FFPE and fresh frozen tissue. Customer feedback praised specimen quality and documentation, with one customer indicating intent to credit iSpecimen as the sample source in publications.
iSpecimen (NASDAQ: ISPC) on March 12, 2026 launched an AI-powered Inventory Agent embedded in its redesigned marketplace to accelerate biospecimen request review and matching. The LLM-driven agent extracts criteria from plain-language requests, ranks potential matches, and aims to reduce manual review while retaining expert oversight.
The company plans additional AI features for regulatory monitoring, workflow automation, and lead qualification to streamline biospecimen sourcing.
iSpecimen (NASDAQ: ISPC) announced completion of Milestone 2: System Integration and Marketplace Activation on February 6, 2026, delivering a live SalesStack production marketplace. Key achievements include end-to-end system integration, full legacy data migration, core feature enablement, AI-assisted matching, and launch of a production site at https://mp.ispecimen.com.
Company says the update enables operational continuity, cost reductions from legacy sunset, improved scalability and performance, and a foundation for supplier onboarding, pricing automation, and broader rollouts ahead of Milestone 3.
iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone on February 6, 2026, collecting 500 influenza swab samples in a few weeks to support a customer research project. The company also reports steady supply of cerebrospinal fluid (CSF) and rising demand for FFPE and fresh frozen tissue specimens. Customer feedback praised specimen quality and documentation for a 20-sample urine shipment and indicated intent to cite iSpecimen as the sample source in publications, underlining continued customer engagement and confidence.